重症肺心病的联合扩血管治疗  

Vasodilater Therapy in Severe Cor Pulmonale Com plicated by Respiratory and Cardiac Failure

作　　者：周红勤[1] 胡婵[1] 汪顺清 宋菊桂 陈九平 

机构地区：[1]湖南省邵阳市第一人民医院心肺血管内科,422001

出　　处：《皖南医学院学报》1999年第1期21-22,共2页Journal of Wannan Medical College

摘　　要：　１１０ 例伴有呼衰和心衰的慢性肺心病（ Ｃ Ｐ Ｈ Ｄ） 者随机分为观察组（６０ 例） 和对照组（５０ 例） ，对照组采用常规治疗，观察组在常规治疗的基础上加用苄胺唑啉（ Ｐ Ｈ Ｌ） 、多巴胺（ Ｄ Ａ） 及卡托普利（ Ｃ Ｐ） 。通过对两组病人的临床和动脉血气的监测发现：扩血管治疗既可显著提高常规治疗的疗效（ Ｐ＜ ００５） ，还可通过促进心肺功能的改善，显著升高 Ｐａ Ｏ２ ，降低 Ｐａ Ｃ Ｏ２（ Ｐ 均＜ ００５） ；未见明显不良反应。To evaluate the effect of vasodilator therapy on severe cor pulmonale ,the clinical phenom ena andarterial blood gas levels were studied in 110 patients with severe cor pulm onale acco m panied by respiratoryfailure and heart failure . Sixty of the m were treated with phentolamine ,dopa mine and captopril on top ofroutine treatment . The results show ed that vasodilator therapy dram atically raised the therapeutic effect ofroutine treatment ( P < 0 .05) , Pa O2 was increased rem arkably ( P < 0 .05) and Pa C O2 w as reducedmarkedly( P< 0 .05) due to im prove ment of the cardiac and pulm onary function . No significant side effectof vasodilator was observed . These findingsindicate that vasodilator therapy is an effective and safe m ethodfor severe cor pulm onale .

关 键 词：肺心病 呼吸衰竭 心力衰竭 扩血管治疗 CPHD 

分 类 号：R541.5[医药卫生—心血管疾病]